The Clorox Company CLX appears in good shape thanks to its robust strategic efforts. The company has been gaining from pricing and cost-saving initiatives for a while now. Its integrated IGNITE strategy focuses on the expansion of key elements under the 2020 Strategy to ramp up innovation across each area of the business. Let’s Delve Deeper Clorox’s robust pricing and cost-saving initiatives have been offsetting elevated manufacturing and logistic costs. These positives have been bolstering the company’s margins for a while now. This led to a gross margin expansion of 40 basis points (bps) year over year during third-quarter fiscal 2024. This marked the sixth consecutive quarter of gross margin expansion on the back of such efforts, somewhat offset by adverse foreign currency fluctuations. For the fiscal 2024, the gross margin is projected to expand nearly 275 bps year over year on gains from lower input cost headwinds and the modest benefit from exiting Argentina. This reflects the combined benefit of pricing actions, cost savings and supply-chain optimization. The company’s streamlined operating model will create a faster, simpler company through the Reimagine Work under its IGNITE strategy. The operating model helps increase efficiency and transforms the company's operations in the areas of the supply chain, digital commerce, innovation and brand building over the long term. The streamlined operating model is expected to enhance the company's ability to respond more quickly to changing consumer behaviors, innovate faster and increase cash flow as a result of cost savings that will be generated primarily in the areas of selling and administration, supply chain, marketing and research and development. However, CLX is reeling under the adverse impacts of inflation and higher manufacturing, logistics and commodity costs. The company has been accelerating investments to enhance digital capabilities. For the fiscal 2024, management anticipates selling and administrative expenses to come between 16% and 17% of net sales, including 2.5 points of impacts of investments to enrich its digital capabilities. Additionally, its results have also been somewhat hurt by lower volumes resulting from the cyberattack and supply-chain inflation. The company is on track with the IGNITE strategy. This strategy encompasses long-term financial targets of achieving net sales growth of 3-5%, EBIT margin expansion of 25-50 bps and free cash flow generation of 11-13% of sales. CLX announced plans to invest $500 million in the next few years in transformative technologies and processes. The investments began in the first quarter of fiscal 2022 and include the replacement of the company's enterprise resource planning system, its transition to a cloud-based platform and the implementation of a suite of other digital technologies. Shares of this producer, marketer and seller of consumer products have gained 5.6% in the past three months compared with the industry’s 2.1% increase. A Growth Score of B further adds strength to this current Zacks Rank #3 (Hold) company. Stocks to Consider in Consumer Staples Space Freshpet FRPT, a pet food company, flaunts a Zacks Rank #1 (Strong Buy). FRPT has a trailing four-quarter earnings surprise of 118.2%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Freshpet’s current financial-year sales and EPS suggests growth of 24.8% and 177.1%, respectively, from year-ago reported numbers. Vital Farms Inc. VITL offers a range of produced pasture-raised foods. It sports carries a Zacks Rank of 1. VITL has a trailing four-quarter average earnings surprise of 102.1%. The Zacks Consensus Estimate for Vital Farms’ current financial-year sales and EPS suggests growth of 22.6% and 62.7%, respectively, from the year-ago reported numbers. Utz Brands Inc. UTZ, which manufactures a diverse portfolio of salty snacks, currently carries a Zacks Rank of 2 (Buy). UTZ has a trailing four-quarter earnings surprise of 2%, on average. The Zacks Consensus Estimate for Utz Brands’ current financial-year EPS suggests growth of 26.3% from the year-ago reported numbers. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Clorox Company (CLX):Free Stock Analysis Report Freshpet, Inc. (FRPT):Free Stock Analysis Report Vital Farms, Inc. (VITL):Free Stock Analysis Report Utz Brands, Inc. (UTZ):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Clorox's (CLX) Pricing & Cost Saving on Track: Apt to Hold?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...